Our latest paper in collaboration with Pfizer on the role of OCT2/MATE in creatinine clearance is accepted in JPET.
Terry’s career in the life science industry spans more than 30 years. He was the CEO of Cambridge based Horizon Discovery Plc, a public company listed on the UK AIM market. During his time at Horizon he lead the growth of the company until its acquisition by Perkin Elmer Corp and spent 6 months ensuring a smooth integration of the business into its new home. He then moved to his current role of CEO at Astrea Bioseperations. Previous roles include VP Global Sales for Pacific Biosciences and lead commercial positions at Genetix PLC, aquired by Danaher Corp., and the Swedish Biotech company Biacore, acquired by GE. Terry started his career in the sector at Applied Biosystems and where he rose to be VP Europe. He graduated with a degree in Physiology and Biochemistry from Reading University.